US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

337.79

+26.148.39%

Number of Gainers:5

Number of Losers:- -

Number of Flat:- -

PE:- -

High:341.69

Open:314.28

Low:314.26

Close:311.66

Loading ...

Press Release: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study

Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today

Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment

Beam Therapeutics receives orphan drug designation for BEAM-302

Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025

THOMSON REUTERS

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS

Beam Therapeutics Inc - to Dose First Patient in Part B of Trial in H2 2025

THOMSON REUTERS

Intellia's Stock Drops Following Adverse Event in Nex-Z Trial

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

MT Newswires Live

Backpack has launched spot trading for WAL, DEEP, SEND, BLUE, HAEDAL, and NS.

J.P. Morgan Remains a Hold on Intellia Therapeutics (NTLA)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (SVRA) and Intellia Therapeutics (NTLA)

Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status

Intellia Therapeutics Updates on Phase 3 Study Progress

Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Transform Therapeutics Globally

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Sui Ecosystem Token Resurgence, SUI Up 7.2% in 24 Hours

Gene Therapy Death Worsens Picture for an Already Troubled Field -- Barrons.com

Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":337.79285,"timestamp":1749239999999,"preClose":311.65695,"halted":0,"volume":24630735,"delay":0,"changeRate":0.083861,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":26.135895,"latestTime":"06-06 16:00:00 EDT","open":314.28003,"high":341.68842,"low":314.2557,"amount":334862241.495393,"amplitude":0.088022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.589944,"peRate":-3.707093,"turnoverRate":0.041958,"increases":5,"decrements":0,"flats":0,"marketCap":6604249784,"floatMarketCap":6363026488},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":341.68842,"amplitude":0.088022,"preClose":311.65695,"low":314.2557,"pbRate":"1.589944","latestPrice":337.79285,"volume":24630735,"delay":0,"open":314.28003,"prevYearClose":376.62552,"prevWeekClose":291.1356,"prevMonthClose":291.1356,"prevQuarterClose":297.7814,"fiveDayClose":291.1356,"twentyDayClose":306.2187,"sixtyDayClose":394.0621,"secType":"PLATE","market":"US","turnoverRate":0.041958,"peRate":-3.707093,"marketCap":6604249784,"floatMarketCap":6363026488,"timestamp":1749239999999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539222635","title":"Press Release: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222635?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:30","pubTimestamp":1748608200,"startTime":"0","endTime":"0","summary":"All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025. Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade--first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLUE","CG","BK4578","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4556","BK4135","IE00B3QW5Z07.USD","BK4139"],"gpt_icon":0},{"id":"2539223844","title":"Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2539223844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539223844?lang=en_us&edition=fundamental","pubTime":"2025-05-30 17:57","pubTimestamp":1748599030,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-intellia-therapeutics-despite-mild-adverse-event-in-phase-3-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-intellia-therapeutics-despite-mild-adverse-event-in-phase-3-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211327993.USD","LU1267930490.SGD","LU0310799852.SGD","LU1861559042.SGD","IE0002270589.USD","LU0070302665.USD","LU1267930573.SGD","BK4559","LU0971096721.USD","LU0029864427.USD","BK4585","LU0130102774.USD","NTLA","LU1280957306.USD","LU0128525929.USD","LU0314106906.USD","LU0251131958.USD","LU0289960550.SGD","LU0310800379.SGD","LU1074936037.SGD","LU1668664300.SGD","BK4556","LU0106831901.USD","LU1861558580.USD","LU0251142724.SGD","LU0310800965.SGD","LU0128525689.USD","BK4501","LU0477156953.USD","LU0980610538.SGD","LU1035773651.USD","LU1814569148.SGD","LU1201861249.SGD","BK4535","LU0320765489.SGD","LU0267386448.USD","LU0154236417.USD","LU0708994859.HKD","BK4207","LU2461242641.AUD","LU2361045086.USD","LU0149725797.USD","IE00B19Z3581.USD","LU1267930227.SGD","LU0072461881.USD","LU0648001328.SGD","LU0683600562.USD","LU1069347547.HKD","LU0640476718.USD","LU2361044949.HKD"],"gpt_icon":0},{"id":"2539290300","title":"Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2539290300","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539290300?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:50","pubTimestamp":1748566214,"startTime":"0","endTime":"0","summary":"20:48 EDT Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ultimate source for rea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-294k-shares-of-crispr-therapeutics-today-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-294k-shares-of-crispr-therapeutics-today-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","ARKK","LENZ","BK4611","BK4539","BK4556","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4585","BK4007","BK4544"],"gpt_icon":0},{"id":"2539299256","title":"Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539299256","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539299256?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:51","pubTimestamp":1748555460,"startTime":"0","endTime":"0","summary":"Beam Therapeutics said the Food and Drug Administration has granted an orphan drug designation to its treatment for a genetic disorder that affects the lungs and or liver.The Cambridge, Mass.-based biotechnology company's drug, BEAM-302, is a liver-targeting lipid nanoparticle formulation that is designed to correct for a mutation in patients with alpha-1 antitrypsin deficiency. AATD, an inherited genetic disorder, leads to early onset emphysema and liver disease.The FDA's orphan drug designation is to support the development and evaluation of treatments for rare diseases that affect fewer than 200,000 people. It includes benefits such as exemption from user fees and seven years of market exclusivity after approval.\"Receiving orphan drug designation for BEAM-302 is an important milestone in our efforts to bring a transformative therapy to people living with AATD, many of whom currently lack effective long-term treatment options,\" said Beam Therapeutics' President Giuseppe Ciaramella.Th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BEAM","LENZ","BK4505","BK4611","BK4007","BK4535","BK4139","BK4588","BK4556","BK4585"],"gpt_icon":0},{"id":"2539229559","title":"Beam Therapeutics receives orphan drug designation for BEAM-302","url":"https://stock-news.laohu8.com/highlight/detail?id=2539229559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539229559?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:11","pubTimestamp":1748549513,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle formulation o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-receives-orphan-drug-designation-for-beam-302-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-receives-orphan-drug-designation-for-beam-302-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BEAM","BK4556","BK4139","BK4505","BK4585","BK4611","BK4588"],"gpt_icon":0},{"id":"2539429310","title":"Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539429310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539429310?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4BDGVK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4611","BEAM","BK4535","BK4505","BK4585","BK4556","BK4139"],"gpt_icon":0},{"id":"2539293103","title":"Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539293103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539293103?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4BDGVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4611","BK4588","BK4505","BK4535","BK4585","BK4139","BEAM"],"gpt_icon":0},{"id":"2539101293","title":"Beam Therapeutics Inc - to Dose First Patient in Part B of Trial in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539101293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539101293?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4BDGVK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4611","BK4585","BK4535","BK4588","BK4556","BEAM","BK4505"],"gpt_icon":0},{"id":"2539262836","title":"Intellia's Stock Drops Following Adverse Event in Nex-Z Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2539262836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539262836?lang=en_us&edition=fundamental","pubTime":"2025-05-29 23:55","pubTimestamp":1748534100,"startTime":"0","endTime":"0","summary":"Shares of Intellia Therapeutics fell after the company reported a grade 4 adverse event in a study of nex-z, its treatment for hereditary ATTR amyloidosis with polyneuropathy.The stock was down 24% to $7.32 on Thursday. Shares have declined 66% in the past 12 months.An asymptomatic patient in the Phase 3 study who was dosed with the treatment had grade 4 liver transaminase elevations, based on laboratory tests, according to a filing with the Securities and Exchange Commission on Wednesday.The effects appear to be resolving without hospitalization or medical intervention, the company said.Analysts at Oppenheimer said in a note they are not overly concerned by the safety findings. There are no signs of liver injury and similar transient liver enzyme elevations previously occurred around a similar timeline in the company's Phase 1 trial, they said.In the over 200 patients dosed with nex-z in the study so far, adverse events are similar to those reported in the drug's Phase 1 study, the co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","BK4535","LU1861559042.SGD","BK4139","BK4588","BK4556","LU1861558580.USD","BK4585"],"gpt_icon":0},{"id":"2539250287","title":"Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250287","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250287?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:26","pubTimestamp":1748521617,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.Shares of the company were down by more than 20% in recent Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NTLA","LU1861559042.SGD","LU1861558580.USD","SSI","BK4096","BK4588","BK4585","BK4535","BK4556","PN"],"gpt_icon":0},{"id":"2539125281","title":"Backpack has launched spot trading for WAL, DEEP, SEND, BLUE, HAEDAL, and NS.","url":"https://stock-news.laohu8.com/highlight/detail?id=2539125281","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539125281?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:05","pubTimestamp":1748516700,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 29, according to the official announcement, Backpack has launched WAL, DEEP, SEND, BLUE, HAEDAL, NS spot trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/296051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["LU0106831901.USD","WAL","BK4578","DEEP","BK4585","BK4588","LU1668664300.SGD","LU1791807156.HKD","BK4556","BLUE","BK4211","BK4589","BK4139"],"gpt_icon":0},{"id":"2539251141","title":"J.P. Morgan Remains a Hold on Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539251141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539251141?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:37","pubTimestamp":1748515035,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Hold rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $12.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-hold-on-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-hold-on-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0225283273.USD","LU0912757837.SGD","LU2357305700.SGD","BK4581","IE00BZ1G4Q59.USD","BK4585","LU1861558580.USD","LU1720051108.HKD","LU1732799900.SGD","LU2347655156.SGD","BK4556","LU0098860793.USD","NTLA","IE00BKVL7J92.USD","BK4588","LU2028103732.USD","BK4139","LU1548497426.USD","LU2023251221.USD","BK4127","LU2271345857.HKD","LU0795875086.SGD","LU1668664300.SGD","LU1162221912.USD","LU2089284900.SGD","BK4535","LU1861559042.SGD","LU1989772923.USD","LU1074936037.SGD","LU0158827948.USD","BK4534","LU1363072403.SGD","LU1989772840.SGD","LU0106831901.USD","LU0106261372.USD","LU0006306889.USD","LU2089283258.USD","LU0267386448.USD","LU2111349929.HKD","LU1720051017.SGD","LU2133065610.SGD","LU1732800096.USD","LU0795875169.SGD","LU0320765646.SGD","BK4504","BK4516","LU0158827781.USD","LU0971096721.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2539251158","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (SVRA) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539251158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539251158?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:30","pubTimestamp":1748514616,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Savara (SVRA – Research Report) and Intellia Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-savara-svra-and-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-savara-svra-and-intellia-therapeutics-ntla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","NTLA","BK4137","BK4556","BK4588","SVRA","HCSG","LU1861558580.USD","BK4535","BK4139","BK4585"],"gpt_icon":0},{"id":"2539981402","title":"Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2539981402","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539981402?lang=en_us&edition=fundamental","pubTime":"2025-05-29 06:10","pubTimestamp":1748470210,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM)’ treatment of alpha-1 antitrypsin deficiency was granted FDA orphan designation status, according to a post to the agency’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-alpha-1-antitrypsin-deficiency-gets-orphan-status-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-alpha-1-antitrypsin-deficiency-gets-orphan-status-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4535","BEAM","BK4556","BK4539","LENZ","BK4007","BK4611","BK4139","BK4585","BK4505"],"gpt_icon":0},{"id":"2539940147","title":"Intellia Therapeutics Updates on Phase 3 Study Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2539940147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539940147?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:59","pubTimestamp":1748465954,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics ( ($NTLA) ) has shared an update. On May 28, 2025, Intellia Therapeutics provided a business update on its Phase 3 studies. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-updates-on-phase-3-study-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-updates-on-phase-3-study-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","BK4535","BK4588","NTLA","BK4139","LU1861558580.USD","LU2065732104.USD","BK4097","PRGS","BK4585","BK4556"],"gpt_icon":0},{"id":"2539409633","title":"Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Transform Therapeutics Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2539409633","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539409633?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:19","pubTimestamp":1748463593,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. has unveiled a corporate presentation detailing a transformative approach to gene editing. The company emphasizes its pioneering work in _in vivo_ gene editing, which involves a simple IV infusion aimed at curing diseases. This method is likened to the transformative impact of mobile smartphones on global communications. Editas highlights its innovative \"plug 'n play\" approach, which allows for the rapid development of new medicines by altering 20 nucleotides to target different diseases. The presentation also addresses challenges faced by recent gene therapy launches, proposing a differentiated therapeutic strategy targeting diseases with higher total addressable markets. The company's strong cash position is reported to provide operational runway into Q2 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL1fFjDv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"gpt_icon":0},{"id":"2539940306","title":"Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2539940306","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539940306?lang=en_us&edition=fundamental","pubTime":"2025-05-29 02:06","pubTimestamp":1748455560,"startTime":"0","endTime":"0","summary":"Forty years after the first statin drug started lowering levels of artery-choking cholesterol, heart attacks and strokes remain the world's biggest killers. This year will see test results on some drugs that cut cholesterol even more.Statins are cheap and effective drugs for reducing blood levels of the \"bad\" cholesterol known as LDL, which gunks up arteries over time. A quarter of Americans have high LDL. But only about half of patients stay on their prescribed statins, and the drugs don't get LDL low enough in some 10% of patients.\"Even with everything that we've done in the field, there is actually a fair amount of new things in the pipeline,\" said researcher Steve Nissen, a cardiologist at the Cleveland Clinic who conducts clinical trials on many of the new drugs.To address these drugs' cost and convenience issues, Merck is testing a pill treatment that it code-named MK-0616. The company is b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","BK4559","LU0320765992.SGD","LU1551013342.USD","AMGN","LU0466842654.USD","LU2602419157.SGD","BK4556","LU1988902786.USD","LU0689472784.USD","LU1934455863.HKD","SG9999001176.SGD","LU0234572021.USD","BK4566","LU1066053197.SGD","AZN","IE00B2B36J28.USD","LU0203202063.USD","LU2237443895.HKD","IE00B1BXHZ80.USD","LU1934455277.USD","LU2237443622.USD","SG9999014880.SGD","BK4611","IE00BSNM7G36.USD","LU2468319806.SGD","SG9999014906.USD","LU0708995401.HKD","LU1814569148.SGD","LU1861558580.USD","LU1035775433.USD","LU2471134523.USD","LU1941712264.USD","LLY","SG9999018857.SGD","LU0786609619.USD","LU2063271972.USD","BK4139","LU1623119135.USD","CRSP","LU0096364046.USD","SGXZ31699556.SGD","LU1804176565.USD","IE0004445239.USD","LU0354030438.USD","LU1989771016.USD","MRK","LU0079474960.USD","LU1720051017.SGD","LU2491050071.SGD"],"gpt_icon":1},{"id":"2538448696","title":"Sui Ecosystem Token Resurgence, SUI Up 7.2% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2538448696","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538448696?lang=en_us&edition=fundamental","pubTime":"2025-05-28 12:05","pubTimestamp":1748405100,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 28, according to HTX market data, the Sui ecosystem tokens saw a rebound, including:SUI's market cap is now at $12.38 billion, with a 24-hour increase of 7.2%;WAL's market cap is now at $760 million, with a 24-hour increase of 8.02%;DEEP's market cap is now at $463 million, with a 24-hour increase of 7.98%;CETUS's market cap is now at $160 million, with a 24-hour increase of 33.2%;BLUE's market cap is now at $39.9 million, with a 24-hour increase of 1.98%;NAVX's market cap is now at $34 million, with a 24-hour increase of 2.75%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/295800","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BLUE","BK4211","BK4139","LU0106831901.USD","LU1791807156.HKD","BK4228","BK4589","BK4215","BK4578","SUI","WAL","BK4556","BK4588","LU1668664300.SGD","BK4585","DEEP"],"gpt_icon":0},{"id":"2538049348","title":"Gene Therapy Death Worsens Picture for an Already Troubled Field -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2538049348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538049348?lang=en_us&edition=fundamental","pubTime":"2025-05-28 00:11","pubTimestamp":1748362260,"startTime":"0","endTime":"0","summary":"The death of a patient in a trial of an experimental gene therapy casts new shadows over a technology once seen as the future of the drug industry.Rocket Pharmaceuticals, a New Jersey-based biotech, said early Tuesday that a patient participating in a small trial of a gene therapy died over the weekend. The therapy is meant to treat a rare genetic condition called Danon Disease, which weakens the heart muscle and generally kills male patients in early adulthood. Rocket shares fell 58.6% on Tuesday.The gene therapy, called RP-A501, was being tested in a Phase 2 trial -- the last step before Rocket planned to submit the treatment for Food and Drug Administration approval. Analysts had been reasonably confident that the trial would be successful: In February, Jefferies analysts Andrew Tsai wrote that he put 65% to 75% odds on a positive readout.Or take Pfizer, which in 2019 unveiled plans to invest hundreds of millions of dollars in a \"state-of-the-art gene therapy manufacturing f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","IE00BJJMRZ35.SGD","BK4139","LU0320765489.SGD","BK4588","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BLUE","IE00BJT1NW94.SGD","BK4585","IE0009355771.USD","RCKT","LU0211331839.USD","NVS","SRPT","BK4532","LU0208291251.USD","BK4007","IE0002141913.USD","LU0070302665.USD","BK4578","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2538660334","title":"Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2538660334","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538660334?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:30","pubTimestamp":1748349023,"startTime":"0","endTime":"0","summary":"Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2pX4sg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4578","BK4556","BLUE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}]}}